Since taking the leadership of Dublin-based Shire PLC early in 2013, Flemming Ornskov has become one of the most visible and outspoken CEOs in the biopharmaceutical sector, boosting his firm as a leader, if not yet the leader, in the rare disease space, and accumulating a string of notable deals, not least last year's merger with Baxalta Inc.
A bit over one year after that transaction was finalized, Ornskov spoke at length with Scrip about his ambitions for Shire going forward, specifically in ophthalmology, hemophilia and hereditary angioedema; the challenges and opportunities in the rare disease space; how his company is paying down the debt from its spate of licensing and M&A
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?